ACCELERATING VACCINE DEVELOPMENT
Solutions to quickly develop your vaccine
Discuss how ABL can support your program!
ABL is attending World Vaccine Congress from April 3-5, 2018 at the Renaissance Washington DC Downtown Hotel in Washington, D.C. Contact us today or visit us at booth 107 to see how ABL can support the development of your vaccine!
Victor Ayala, Ph.D., an ABL Staff Scientist, will be presenting during the conference:
“Accelerating Vaccine Production Using a Non-viral Enabling Technology for Cell Engineering.”
During his presentation, Dr. Ayala will:
Discuss Phase I, fully-scalable technology that allows efficient, cost-effective evaluation of vaccine candidates.
Talk about the role media has on antigen folding, expression and glycosylation for transfection.
Review customized purification techniques and characterization assays to overcome variability.
As a CRO and CMO with over 50 years of experience partnering with clients to meet their product development goals, ABL provides contract manufacturing and laboratory research services to advance leading vaccines and therapies from preclinical development to the commercial market.
Phenotyping • Biomarker Quantitation
Receptor Occupancy • Binding Affinity • Sample Processing
Viral Vector and Oncolytic Virus Manufacturing • Protein Production • and more!
Download our service brochures below or contact us now to speak with one of our experts:
NAJÍT TECHNOLOGIES PARTNERS WITH ABL FOR DEVELOPMENT OF NOVEL VACCINE PLATFORM
ABL is working with Najít Technologies, Inc. to advance the development of Najít’s novel HydroVax™ vaccine platform.